Lonza to manufacture Alector’s mAb drug candidates for Ph I trial 09-May-2019 By Maggie Lynch Lonza will provide manufacturing for Alector’s Phase I drug candidates for neurodegenerative diseases from its Switzerland site, which is expected to be operational by mid-2020.
Hired and retired: Year’s end edition 13-Dec-2018 By Ben Hargreaves As we move closer to the end of the year, companies are assembling their boardrooms ready for the new year.